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Simvastatin and Atorvastatin inhibit DNA replication
licensing factor MCM7 and effectively suppress
RB-deficient tumors growth
Juan Li1,2,9, Jie Liu1,2,9, Zheyong Liang1,2, Fang He1,2, Lu Yang1,2, Pingping Li1,2, Yina Jiang3, Bo Wang1,2, Can Zhou4, Yaochun Wang1,2,
Yu Ren4, Jin Yang5, Jianmin Zhang6, Zhijun Luo7, Cyrus Vaziri8 and Peijun Liu*,1,2
Loss or dysfunction of tumor suppressor retinoblastoma (RB) is a common feature in various tumors, and contributes to cancer
cell stemness and drug resistance to cancer therapy. However, the strategy to suppress or eliminate Rb-deficient tumor cells
remains unclear. In the present study, we accidentally found that reduction of DNA replication licensing factor MCM7 induced more
apoptosis in RB-deficient tumor cells than in control tumor cells. Moreover, after a drug screening and further studies, we
demonstrated that statin drug Simvastatin and Atorvastatin were able to inhibit MCM7 and RB expressions. Further study showed
that Simvastatin and Atorvastatin induced more chromosome breaks and gaps of Rb-deficient tumor cells than control tumor cells.
In vivo results showed that Simvastatin and Atorvastatin significantly suppressed Rb-deficient tumor growth than control in
xenograft mouse models. The present work demonstrates that ‘old’ lipid-lowering drugs statins are novel weapons against
RB-deficient tumors due to their effects on suppressing MCM7 protein levels.
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Retinoblastoma (RB) gene, a well-studied tumor suppressor,
plays important roles in cell-cycle regulation and other cellular
processes.1–3 Loss or dysfunction of RB is a common feature
in various tumors, and contributes to tumor cell stemness and
drug resistance.4,5 Therefore, it is urgent to explore a way to
suppress RB-deficient tumor cells.
We accidentally found that acute depletion of mini-
chromosome maintenance protein 7 (MCM7), a DNA replica-
tion licensing factor, could induce more apoptosis in
RB-deficient tumor cells than in control cells. Therefore,
MCM7 might be an ideal target for suppressing RB-deficient
tumor cell growth. MCM7 is one component of MCM2-7
hexamer (MCMs). The MCM2-7 complex forms the core of the
DNAhelicase and is responsible for melting and unwinding the
double helix during DNA synthesis.6–8 Recent studies have
demonstrated that the chromatin-bound excess MCM com-
plex plays an important role in maintaining genomic integrity
under conditions of replicative stress in human cells, and that
acute ablation of MCMs induces chromosome fragility in
cells.9–11 DNA replication licensing factor MCM2-7 proteins
are highly expressed in various clinical tumor tissues.12–16
Reduction of MCMs causes tumor cells to become sensitive to
chemotherapy drugs;11,17 thus, excess MCMs in tumor cells
might serve as a shield to resist antitumor chemotherapy.
Remarkably, depletion or mutation of a single MCM in
mammalian cells by siRNA-mediated approaches results in
suppression of all functional MCMs due to the hexameric
dependency of the MCM complex for helicase activity,9,11,18,19
and cells might own a sensing mechanism that maintains
equal MCM subunit stoichiometry.20,21
In the present study, we demonstrated that reduction of
MCM7 inducesmuchmore γ-H2AX expression and apoptosis in
RB deficient or inactive tumor cells than in RB-proficient tumor
cells. Small molecular drug screening and further experiments
demonstrated that Simvastatin (SVA) and Atorvastatin (ARO)
could suppress MCM7 protein expression effectively. SVA and
ARO are members of statins, well known as small-molecule
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase that can lower cholesterol. Numerous studies,
employing a variety of tumor cells, have demonstrated their
antitumor effects.22–24 Nevertheless, the mechanisms for these
anticancer effects are still not well characterized.
The aim of this study is to verify whether MCMs is a target for
anti-RB-deficient tumor therapy, and to further clarify the
antitumor effect and potential mechanism of the statin drugs.
Results
Acute depletion of MCM7 induces γ-H2AX expression
and apoptosis in RB-deficient or inactive tumor cells.
Numerous studies have shown that DNA replication licensing
factors are overexpressed in various tumor cells and clinical
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Figure 1 Acute depletion of MCM7 expression induced γ-H2AX expression and apoptosis in RB inactive or deficient tumor cells. (a) RB expression in human osteosarcoma
cell lines U2OS/SaOS2 and human cervical cancer cell lines SiHa/C33A. (b) SiHa cells and C33A cells were transfected with siMCM7 or sicontrol for 72 h. The resulting cells
were analyzed by immunoblotting with antibodies MCM7, RB and γ-H2AX. (c) U2OS cells and SiHa cells were transfected with siMCM7 or sicontrol for 24 h, then infected with
HPV E7 adenovirus or control adenovirus to deplete RB expression for 48 h. The resulting cells were analyzed by immunoblotting with antibodies MCM7, RB or γ-H2AX. (d)
SaOS2 cells and C33A cells were transfected with siMCM7 and sicontrol for 24 h, then infected with Adpsm-RB adenovirus or control adenovirus to activate RB for 48 h. The
resulting cells were analyzed as described above. (e and f) U2OS cells, SiHa cells, SaOS2 cells and C33A cells were treated as above. The resulting cells were then incubated
with annexin V-FITC and PI, then examined by FACS. (g and h) Proteins involved in DNA damage repair were analyzed by western blotting. U2OS, SiHa, SaOS2 and C33A cells
were treated with siRNA and adenovirus as described above. Equal protein loading was evaluated by β-actin. Data were represented as mean±S.D of the three independent
expressions
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tissues;12–14 therefore, excess MCMs in tumor cells might
serve as a shield to protect tumor cells against antitumor
chemotherapy. Studies have also shown that depletion of
MCM7 results in disruption of whole MCMs hexamer
complex.9,11,18,19 To test the role of MCMs in maintaining
cell chromosomal integrity, the RB expression levels of
U2OS/SaOS2/SiHa/C33A cancer cells were detected
(Figure 1a). Then, MCM7 was silenced in SiHa and C33A
cells, and DNA double-strand break (DSB) marker protein
γ-H2AX was detected. As shown in Figures 1b, significant
reduction of MCM7 expression was achieved, and depletion
of MCM7 led to a reduction in RB protein levels. This result is
fully expected based on our published work: in MCM7-
depleted cells, there is reduced replication licensing leading
to attenuation of several cell-cycle-regulated genes, including
RB whose expression is transcriptionally induced in G1.26
Interestingly, γ-H2AX was also detectable in
RB-deficient C33A cells after MCM7 knockdown. These
results indicated that RB status may be important for the DNA
DSBs after MCM7 depletion. To further investigate the effect
of MCM7 depletion in treatment of RB-proficient and
RB-deficient tumors, AdE7 adenoviruses, which express
human papillomavirus (HPV) E7 oncoprotein and degrade
RB protein,27–29 was used to infect RB-proficient U2OS and
SiHa cells; and AdPSM-RB adenoviruses, which express an
active allele of RB protein,30 was used to restore active RB in
RB-deficient SaOS2 and C33A cells. In this study, the active
RB allele PSM is a truncation mutant that contains the pocket
domain but is smaller than full-length RB protein. PSM-RB
lacks epitopes that are recognized by most commercial RB
antibodies, including the antibodies used in our study.
Therefore, as a surrogate for measuring RB activity in
AdPSM-RB-infected cells, we examined expression of Cyclin
E (a repressed transcriptional target of RB – see Figures 1c
and d). We also confirmed expression of PSM-RB mRNA
(using RT-PCR) in AdPSM-RB-infected cells (Supplementary
Figure S1b). As shown in Figures 1c and d, MCM7 depletion
resulted in stronger expression of γ-H2AX after HPV E7
adenovirus infection in SiHa and U2OS cells, and MCM7
depletion induced a weaker expression of γ-H2AX in PSM-
RB adenovirus-infected C33A and SaOS2 cells. Then,
MCM7 and RB were silenced using siRNA in SiHa and
U2OS cells and the effects of MCM7/RB-ablation on γ-H2AX
were determined. As shown in Supplementary Figure S1a,
co-depletion of MCM7 and RB led to increased γ-H2AX,
thereby fully recapitulating the effects of HPV E7 on γ-H2AX
when MCM7 is depleted. These results strengthen our
conclusion that RB allows cells to tolerate reduced MCM7
expression.
γ-H2AX is known as a sensor for DNA DSBs, and apoptosis
is one of the results of DNADSB.31,32 Thus, we asked whether
depletion of MCM7 gave rise tomore apoptosis in RB-deficient
tumor cells. The FACS results showed that MCM7 depletion
resulted in more apoptosis in HPV E7 adenovirus-infected
U2OS and SiHa cells (Figure 1e), and that MCM7 depletion
led to a larger apoptotic population in SaOS2 and C33A
RB-deficient tumor cells (Figure 1f).
DNA DSBs trigger DNA damage response (DDR) check-
point to repair the damaged DNA, and cell apoptosis is one of
the outcomes of DDR response.33–35 Here, we asked whether
RB status is crucial for activation of DDR checkpoints. RB
inactive (AdE7 infected) and deficient tumor cells showed
elevated p-ATM, p-ATR, p-Chk1, p-Chk2 and p-p53 expres-
sions, and that PSM-RB restored C33A and SaOS2 cells
showed weaker expression of those proteins, and that total
DNA damage checkpoint proteins were not changed
(Figures 1g, h, Supplementary Figures S1c and d). Taken
together, our results showed that RB inactive or deficient
tumor cells were more sensitive to acute MCM7 depletion, and
that acute MCM depletion induced stronger DDR response in
RB-deficient tumor cells than in control tumor cells.
SVA or ARO inhibits MCM7 and RB protein expressions
and induces apoptosis in Hep3B cells. Based on the
above observation, to further explore which small molecular
drug(s) can inhibit MCM7 protein expression, a small
molecular drug screening was carried out and SVA showed
the strongest inhibition effect on MCM7 protein (Figure 2a).
To identify which statins were more effective to inhibit MCM7
expression, we screened five clinically used statins and
identified their capacities for inhibiting MCM7 expression. We
found that SVA and ARO exhibited more inhibitory effect on
MCM7 protein expression than the other statins. Moreover,
we found that SVA and ARO could effectively reduce both the
MCM7 and RB protein expressions (Figure 2b).
To determine the effects of SVA or ARO on cell-cycle
progression, Hep3B cells were treated with different concen-
trations of SVA or ARO. The percentages of the G2/M phase
cells were reduced, and that the percentages of apoptotic cells
in the sub-G1 phase were significantly increased at 72 h
following the treatment (Figure 2c). Our experiments showed
that expressions of MCM7, RB, p-RB and S-phase proteins
CDC45 and PCNA were reduced while expressions of G1
phase inhibitors p21 and p27 proteins were increased after
SVA or ARO treatment (Figure 2d).
Antiapoptotic protein Bcl2 was reduced, apoptosis protein
cleaved-caspase-3 increased andDSB sensor protein γ-H2AX,
which is an apoptosis-related protein,31 increased 72 h after
SVA or ARO treatment (Figure 2e). Immunofluorescence assay
showed the presence of γ-H2AX after SVA or ARO treatment
(Figure 2f). These data suggest that SVA or ARO decreased
G2/M phase population and induced apoptosis.
SVA suppresses MCM7 and RB protein expressions via
activating endoplasmic reticulum stress and autophagy
signaling pathway. To investigate the mechanism(s) by
which SVA led to reduced expression of MCM7 and RB, the
mRNA expression levels of MCM2, MCM4, MCM7 and RB
were analyzed. Interestingly, the mRNA expression levels of
all licensing factors and RB increased after SVA treatment
(Figure 3a), while the protein expression levels of MCM7 and
RB decreased after SVA treatment (Figure 3b). Our results
showed that reduction of MCM7 and RB protein after SVA
treatment was not due to the reduced transcription activity.
We next investigated whether MCM7 and RB were
degraded by ubiquitin proteasome system (UPS). Our experi-
ments showed that MG132 did not recover the SVA-reduced
MCM7 and RB protein expression levels (Figure 3c). These
data indicated that reduction of MCM7 and RB proteins after
SVA treatment were not due to UPS activation.
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Figure 2 Statins inhibited the expressions of MCM7 and RB and induced apoptosis and DNA damage. (a) A small molecular drug screening was carried out and SVA showed
strongest inhibition effect on MCM7 protein. (b) MCM7 and RB expressions were inhibited after Hep3B cells were treated for 24 or 72 h with 5 or 10 μM Simvastatin, 20 and
40 μM Atorvastatin, 50 and 100 μM Fluvastatin, 10 and 20 μM Lovastatin, and 10 and 20 μM Pravastatin. (c) Hep3B cells were treated with Simvastatin (10 μM), Atorvastatin
(40 μM) and Pravastatin (20 μM) for 72 h, harvested and incubated with PI, and then analyzed by FACS. Statistical analysis showed differences in the G0/G1 phase and the
sub-diploid peak between drug-treated cells and control cells. (d) Hep3B cells were treated with Simvastatin (5 or 10 μM) or Atorvastatin (20 or 40 μM) for 24 or 72 h, and cell
extracts were analyzed by immunoblotting. The expression of MCM7, RB, p-RB, cyclin D1, PCNA and CDC45 were reduced and the expressions of p21 and p27 were increased.
(e) Hep3B cells were treated as above; cell extracts were analyzed by immunoblotting with Bcl2, γ-H2AX, PARPor cleaved-caspase3 antibodies. (f) Hep3B cells were treated with
10 μM Simvastatin or 40 μM Atorvastatin for 72 h, then incubated with γ-H2AX antibody and imaged by laser confocal microscopy (scale bars, 10 μm)
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Reportedly, statins can activate AMPK,35–37 endoplasmic
reticulum (ER) stress and autophagy signaling pathway,38,39
and inhibit the mTOR pathway.40 We tested whether serum
starvation-induced autophagy affected MCM7 and RB
expression. After serum starvation, MCM7 and RB mRNA
expressions were significantly increased, while their protein
expressions showed no change (Figures 3d and e). Then, we
determined whether SVA activated ER stress and autophagy
signaling pathway. We found that p-AMPK, p-PERK, p-eIF2α
and LC3A/B were increased and p70S6 was decreased after
SVA treatment (Figures 3f, g and i). We also found that
compound C (AMPK inhibitor) and GSK2606414 (PERK
inhibitor) effectively reversed the MCM7 and RB protein
expression (Figures 3h and j). Taken together, our results
Figure 3 Simvastatin reduced MCM7 and RB expressions via activating cell autophagy and ER stress signaling pathway. (a) Hep3B cells were treated with 5 or 10 μM
Simvastatin for 24 or 72 h. The mRNA expression levels of MCM2, MCM4, MCM7 and RB in the resulting cells were analyzed by RT-PCR. (b) MCM7 and RB expressions were
decreased after Simvastatin treatment. Hep3B cells were treated with 5 or 10 μM Simvastatin for 24 or 72 h, and then analyzed by immunoblotting with MCM7 or RB antibodies.
(c) Hep3B cells were treated with 2 μMMG132 and 10 μM Simvastatin for 48 h, then harvested and analyzed by immunoblotting with MCM7 and RB antibodies. (d and e) Hep3B
cells were cultured with 10% FBS or 0.01% FBS for 24 h and subjected to DNA content analysis using a FACS flow cytometer; or analyzed the expression of MCM7 and RB by
RT-PCR and immunoblotting. (f) Hep3B cells were treated with 5 or 10 μM Simvastatin for 24 or 72 h, and then cell extracts were analyzed by immunoblotting with AMPK cell
signaling or cell autophagy-related antibodies. (g) Hep3B cells were treated with serum starvation or 5 μM Simvastatin for 72 h. Cell monolayers were fixed and stained with
LC3A/B, and immunofluorescence images were presented (Scale bars, 10 μm). (h) Hep3B cells were treated for 48 h with 5 μM compound C (AMPK inhibitor; Sigma-Aldrich,
St. Louis, MO, USA) or 10 μM Simvastatin, then harvested and analyzed by immunoblotting with p-AMPK, MCM7 or RB antibodies. (i) Hep3B cells were treated with 5 or 10 μM
Simvastatin for 24 h or 72 h, and then cell extracts were analyzed by immunoblotting with PERK, p-PERK and p-eIF2α antibodies. (j) Hep3B cells were treated for 48 h with 2 μM
GSK2606414 (PERK inhibitor; Millipore, Bedford, MA, USA) or 10 μM Simvastatin, then harvested and analyzed by immunoblotting with p-PERK, MCM7 or RB antibodies
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indicated that SVA inhibited MCM7 and RB protein expres-
sions by activating ER stress and the autophagy signaling
pathway.
SVA inhibits tumor proliferation and sensitizes
RB-deficient or inactive tumor cells. To further demon-
strate the broad inhibitory effect of SVA on different tumor cells,
the RB and p-RB protein expression of paired U2OS and
SaOS2 human osteosarcoma cells, SiHa and C33A human
cervical cancer cells, and LNCaP and Du145 human prostate
cancer cells were examined. RB proteins were not detectable
or weakly expressed in SaOS2, C33A and Du145 cells, in
contrast with their paired U2OS, SiHa and LNCaP cells
(Figure 4a). Then the paired cancer cells were treated with
different dosages of SVA. Cells that survived were harvested
and counted at different time points (Figure 4b). We found that
RB-deficient cells were more sensitive to SVA than RB-
proficient cells (Figure 4c). Apoptosis proteins cleaved-PARP
and cleaved-caspase-3 were detectable after 72 h SVA
treatment, and apoptosis inhibitory protein Bcl2 were
decreased after SVA treatment for 72 h (Figure 4d). Flow
cytometry experiments also showed that the pre-G1 apoptotic
cell populations were significantly increased in RB-deficient
C33A and Du145 cells (Supplementary Figures S2a–c).
Taken together, our results demonstrated that SVA could
inhibit proliferation of various tumor cells, and that RB-deficient
cells were more sensitive to the SVA treatment than
RB-proficient cells.
SVA increases chromosome instability in RB-deficient
cells. We investigated the possible mechanism(s) by which
SVA induced apoptosis in RB-proficient and RB-deficient
cells. Chemical cytotoxicity is usually associated with
endogenously generated reactive oxygen species (ROS),
but we found that ROS was not detected after SVA treatment
(Supplementary Figure S3). It suggested that SVA exerted
apoptotic effects were not induced by the increase in
oxidative stress.
Then we detected γ-H2AX expression in RB-proficient and
-deficient cells. The result showed detectable γ-H2AX in
SaOS2 and C33A cells, but no γ-H2AX in U2OS and SiHa
cells after SVA treatment (Figure 5a). After SVA treatment,
RB-depleted U2OS cells showed a significantly increased
Pre-G1 apoptotic cell population, and γ-H2AX was detectable
in RB-depleted U2OS cells, but barely detected in control cells
(Figures 5b–e).
Since SVA induced the expression of γ-H2AX in
RB-depleted tumor cells, we asked whether SVA could
activate DDR response. After SVA treatment, DDR checkpoint
proteins (p-ATM, p-CHK2 and p-p53) were increased at an
earlier time points in SaOS2 and C33A cells than in U2OS and
SiHa cells. Seventy-two hours after SVA treatment, those
active DDR checkpoint proteins were significantly impaired in
SaOS2 and C33A cells, compared with those in U2OS and
SiHa cells (Figure 5f).
Ibarra and others11 have reported that cells with reduced
backup MCMs are sensitive to replicative stress and display
chromosome instability after treatment with DNA replication
inhibitor aphidicolin. Therefore, we asked whether SVA could
induce chromosome instability and whether RB status was
related to chromosome instability. We found that RB-deficient
SaOS2 cells displayedmore breaks and gaps thanU2OS after
SVA treatment (Figure 5g).
Taken together, compared with RB-proficient cells, RB-
deficient cells showed highly increased chromosome instabil-
ity and significantly impaired DDR checkpoint proteins 72 h
after SVA treatment, which suggests that irreparable chromo-
some damage might be a cause of cell apoptosis.
RB-deficient tumors were more sensitive to SVA than
RB-proficient tumors in vivo. To investigate whether SVA
can inhibit tumor growth in vivo, mouse melanoma B16 cells
were subcutaneously injected into C57 mice, and mouse
breast carcinoma 4T1 cells were injected into the fat pad of
BalB/C mice. When tumors grew to the size of 4 mm×4 mm,
mice were treated with water or SVA (60 mg/kg/day) via
taking gavage. B16 and 4T1 tumors were significantly redu-
ced after SVA treatment (Figures 6a–c and Supplementary
Figures S4a–c). Immunohistochemistry showed that MCM7-
positive and RB expression were reduced after SVA treat-
ment (Figures 6d, e and Supplementary Figure S4d).
Next, we determined whether RB-deficient tumor was more
sensitive to SVA than RB-proficient tumor in vivo. SiHa human
cervical cancer cells were infected with control adenovirus and
HPV E7 adenovirus. Forty-eight hours after the infection,
adenovirus-infected cells were subcutaneously injected into
nude mice. The growth of AdE7-infected SiHa tumor was
significantly decreased after SVA treatment, and the inhibitory
effects were dosage-dependent (Figures 6f–h). Immunohisto-
chemistry showed that MCM7 and RB proteinswere reduced in
AdE7-infected tumor cells after SVA treatment. These experi-
ments showed that MCM7 and RB were reduced after SVA
treatment and that RB-deficient tumor was more sensitive to
SVA than RB-proficient tumor in vivo (Figures 6i and j).
Taken together, the present study demonstrated that statin
drugs such as SVA could effectively inhibit MCM7 and RB via
activation of ER stress and autophagy signaling cascade, and
that reduction of MCM7 and RB induced more chromosome
breaks or gaps and further gave rise to apoptosis in
RB-deficient tumor cells (Figure 6k).
Discussion
In the present study, we reported for the first time that
reduction of licensing factor MCM7 induced more γ-H2AX
expression and apoptosis in RB inactive or deficient tumor
cells than in RB-proficient tumor cells. Various reports have
shown that DNA replication licensing factors, such as CDC6,
CDT1 andMCMs, are overexpressed in different clinical tumor
samples and tumor cell lines.12–14 Excess MCM proteins
protect human cells from replication stress,9,11 so tumor cells
owning excess MCMs may act as a ‘shield’ against chemical
drugs which induce replication stress. Reduction of licensing
factor MCMs has been considered a potential strategy to
disarm the tumor cells’ ability to resist against replication
stress-inducible chemotherapy drugs.17 In this study, we found
that RB status was essential to this effect of MCMs reduction.
RB, a gatekeeper gene of the G1 phase, is phosphorylated
when Pre-RC properly assembles and allows cells to enter the
S-phase for DNA replication. RB monitors the assembly of
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Pre-RC.15,16 Our finding will provide a potential strategy for
RB-deficient tumor therapy since loss or inactivation of RB is a
common feature of more than half of human tumors.
Interestingly, we found that MCM7 depletion resulted in
stronger expression of γ-H2AX in HPV E7 adenovirus-infected
SiHa and U2OS cells than in control adenovirus-infected cells.
As is well known, high-risk HPVs (HPV16, 18, etc.) are
important risk factors in various tumors; most cases of cervical
cancer are associated with HPV infections, such as HPV16
and HPV 18 infections.29,41,42 Therefore, the results of our
study also identify MCM7 as a potential therapeutic target not
only in RB-deficient tumors but also in HPV-expressing
malignancies, thereby broadening the significance of our
findings.
After a small molecular drug screening, we found that SVA
could inhibit MCM7 protein levels more effectively. Statins,
inhibitors of HMG-CoA reductase and well-known cholesterol-
lowering drugs, have been used in clinic for almost 40 years
and have been proved to be safe, effective drugs with minor
side effects.43–45 Randomized controlled clinical trials have
indicated that statins have provocative and unexpected
benefits for reducing the incidence of colorectal cancer and
Figure 4 RB-deficient or inactive tumor cells were more sensitive to Simvastatin than RB-proficient cells. (a) The expression status of RB in different cells. Extracts of U2OS/
SaOS2/SiHa/C33A/LNCaP/Du145 cells were analyzed by immunoblotting with MCM7 or RB antibodies. (b) The cell survival rates of U2OS, SaOS2, SiHa, C33A, LNCaP and
Du145 cells after treatment with Simvastatin for 24, 48 or 72 h. The viable cells were harvested and counted three times for each treatment. (c) U2OS and SaOS2 cells were
treated with 5 μM Simvastatin for 72 h, incubated with annexin V-FITC and PI, and then examined by FACS. (d) U2OS/SaOS2 and SiHa/C33A were treated with Simvastatin
(2.5 or 5 μM) for 24 or 72 h, and then cell extracts were analyzed by immunoblotting with apoptosis-related antibodies
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melanoma.46–48 Statins can also inhibit tumor growth via
different mechanisms, such as inhibition of angiogensis or
inflammation.49,50 Our results showed that SVA or ARO
displayed a stronger effect on inhibiting MCM7 expression in
various tumor cells. Interestingly, SVA or ARO not only
effectively reduced the MCM7 protein expression in various
tumor cells, but also effectively reduced the RB protein
expression. Moreover, we also observed herein that
RB-deficient or inactive tumor cells displayed higher expres-
sion of γ-H2AX and higher sensitivity to SVA treatment than
RB-proficient tumor cells. Our finding will broaden the
application of SVA or ARO to RB-deficient tumor therapy.
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Several reports have shown that various RB-deficient
tumors are drug resistant.4,5,51 For instance, tamoxifen
(TAM)-resistant breast cancer cells display stem cell-like traits
and loss of RB function.4,5 Statins can re-sensitize those TAM-
resistant breast cancer cells to chemo-drugs.52,53 Our work
present here may provide a clue for exploring the mechanisms
by which statins inhibit proliferation of TAM-resistant breast
cancer cells or other chemo-drug-resistant tumor cells in the
process of tumor therapy.
Ibarra and co-workers have reported that depletion of
licensing factor MCMs induces chromosome break and gap.11
As DNA damage or chromosome instability is a common cause
of cell-cycle arrest and apoptosis, one of the earliest events in
DNA damage is the initiation of histone H2AX phosphorylation
on Ser139 to generate γ-H2AX, which forms nuclear foci and
recruits DNA repair factors.54,55 Our results showed that SVA
and ARO treatment resulted higher γ-H2AX expression in
RB-deficient tumor cells than in RB-proficient tumor cells. We
also found that RB-deficient SaOS2 cells displayed more
breaks and gaps than RB-proficient U2OS cells after SVA
treatment. Since DNA damage initiates DDR response in cells
and DDR inhibition triggers apoptosis signaling cascade, we
examined the expression of DDR response checkpoint proteins
at different time points after SVA treatment. Our results
demonstrated that SVA or ARO inhibited DDR checkpoint
proteins activation at later time points in RB-deficient tumor
cells than in RB-proficient tumor cells. SVA or ARO also
induced more chromosome breaks or gaps in RB-deficient
tumor cells than inRB-proficient tumor cells. Evidence indicates
that tumor development is associated with perturbed DDR
repair pathways. Defects in one DDR repair pathway can be
compensated by other pathways, which may contribute to
resistance to DNA damage chemotherapy and radiotherapy.
Therefore, DDR pathways make an ideal target for therapeutic
intervention.33,35,55,56 Our results demonstrated that SVA or
ARO effectively inhibited activities of RB and other DDR
checkpoint proteins in various tumor cells 72 h after treatments.
These results support the point of view that DDR pathways are
ideal targets for tumor therapy.
In vivo results showed that SVA effectively reduced the size
and weight of xenograft tumors and inhibited MCM7 and RB
protein expressions in mice. What is more, although the mice
remained healthy after treatment with high-dosageSVA (60 mg/
day/kg in mice amount to about 5.4 mg/kg/day in human), a
dosage much higher than what is used for patients, whether
high-dosage SVA can effectively inhibit tumor development in
clinic should be investigated. This finding also provided
evidence for the potential of statins in tumor treatment.
Although previous reports have shown that MCMs serve as
potential targets for tumor therapy, an important problem
should be pointed out: partial suppression of MCMs function
can give rise to increased genomic instability and DNA
damage.11,17 MCM4 knockout mice display genomic instability
and mice with sustained, partially defective MCMs function
display increased cancer risk.57–60 We provide here that SVA
or ARO reduces MCM7 and RB protein expressions, induces
chromosome instability and gives rise to apoptosis in various
tumor cells. Statins have been used almost four decades and
have been proved safe. No evidence shows that statins result
in tumor; instead randomized controlled clinical trials indicate
that statins have unexpected benefits of reducing tumors.43-45
To our knowledge, this is the first report showing that: (1)
RB-deficient or inactive tumor cells are more sensitive to
MCMs reduction; (2) statin drug SVA or ARO inhibits the
protein expression of licensing factor MCM7 and RB via
activating ER and autophagy signaling pathway; (3) SVA or
ARO induces a higher apoptosis rate in RB-deficient cells than
in RB-proficient cells; (4) SVA or ARO triggers DDR
checkpoint cascade at earlier time point and induces more
chromosome breaks or gaps in RB-deficient tumor cells than
in RB-proficient tumor cells. These findings suggest that statin
drugs, such as SVA and ARO, may be potential anti-RB-
deficient tumor drugs, and may provide new insights for
application of ‘old’ lipid-lowering statin drugs to tumor therapy.
Materials and Methods
Cell culture and treatments. SiHa and C33A human cervical cancer cells,
Hep3B human liver cancer cells and 4T1 mouse mammary gland cells were
cultured in high-glucose DMEM (HyClone, Logan, UT, USA) and 10% fetal bovine
serum (Gibco, Grand Island, NY, USA). LNCaP and Du145 human prostate cancer
cells and B16 mouse melanoma cells were cultured in RPMI-1640 medium (Hyclon)
and 10% fetal bovine serum (Gibco). U2OS human osteosarcoma cells were
cultured in McCoy's 5a medium (Hyclon) and 5% fetal bovine serum (Gibco) and
10% horse serum (Gibco). SaOS2 human osteosarcoma cells were cultured in
McCoy's 5a medium and 15% fetal bovine serum. All cell lines purchased from
Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences
(Shanghai, China).
Cell lines were authenticated by short-tandem repeat analysis by the cell bank.
For siRNA (Invitrogen, Carlsbad, CA, USA), cells were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Target
sequences of oligonucleotides used were as follows: Control (Non-Targeting), 5′-
UUC UCCGAA CGU GUC ACG U-3′ and 5′-ACG UGA CAC GUU CGG AGA A-3′;
MCM7-1, 5′-AUC GGA UUG UGA AGA UGA A-3′ and 5′-UUC AUC
UUC ACA AUC CGA U-3′; MCM7-2, 5′-GCU CCA GAU UCA UCA AAU U-3′ and
5′-AAU UUGAUGAAU CUGGAG C-3′; RB1, 5′-AAU GGU UCACCU CGA ACAC-3′
and 5′-GGGUGU UCG AGG UGA ACC A-3′; RB-2, 5′-GAA ACA GAA
GAA CCU GAU U-3′ and 5′-AAU CAG GUU CUU CUG UUU C-3′.
The Simvastatin prodrug (Sigma-Aldrich) was subjected to activation as described
by Sadeghi et al.25 Atorvastatin, Lovastatin, Fluvastatin and Pravastatin were
purchased from Sigma-Aldrich. Atorvastatin was dissolved in methanol. Lovastatin
Figure 5 Simvastatin was more likely to induce chromosome instability and γ-H2AX expression in RB deficient or inactive tumor cells than in RB-proficient cells. (a)
Simvastatin induced γ-H2AX expression in RB deficient or inactive tumor cells. U2OS, SaOS2, SiHa and C33A cells were treated with 5 μM Simvastatin for 72 h, and then
analyzed by immunofluorescence staining with γ-H2AX antibody. (b and c) U2OS cells were transfected with siRB-1 and siRB-2 for 48 h to deplete RB. Then cells were treated
with 5 μM Simvastatin for 72 h, incubated with PI and analyzed with FACS. The result was compared with that of control cells, statistical analysis of the difference in sub-diploid
peak between drug-treated cells and control cells. (d and e) U2OS cells were depleted of RB by siRB and treated with Simvastatin (2.5, 5 or 10 μM) for 72 h. The resulting cells
were analyzed by immunofluorescence staining or immunoblotting with γ-H2AX antibody. (f) U2OS, SaOS2, SiHa and C33A cells were treated with 2.5 or 5 μM Simvastatin for 24
or 72 h; then cells extracts were analyzed by immunoblotting with p-ATM, p-ATR, p-CHK1 or p-CHK2 antibodies. (g) Simvastatin induced more DNA damage in RB deficient or
inactive tumor cells. U2OS and SaOS2 cells were treated with 5 μM Simvastatin for 72 h. Chromosomal instability was examined as described and chromosome gaps (white
boxes) and breaks (black boxes) were scored
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was dissolved in ethanol. Fluvastatin and Pravastatin were dissolved in double
distilled H2O.
Immunoblot analysis. Protein extracts were prepared from cell cultures. For
immunoblotting analysis, protein extracts were separated on 6–12% SDS-PAGE gels
and transferred onto PVDF membrane (Millipore, Bedford, MA, USA). The membrane
reacted with primary anti-MCM7, anti-p27, anti-Bcl2 (Santa Cruz, CA, USA),
anti-γ-H2AX (Millipore) and the other antibodies (Cell Signaling Technology, Beverly,
MA, USA). Proteins were visualized by chemiluminescence reagent (Cell Signaling).
Real-time PCR. mRNA expression was analyzed using SYBR Green (TaKaRa,
Dalian, China). Quantitative PCR analyses were performed with the Bio-Rad
CFX96TM Real-Time PCR detection system and analyzed using the CFXTM
manager 3.0 (BioRad, CA, USA). The PCR mixtures were prepared, and the
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reactions were visualized according to the TaKaRa product manual. Each
experiment was performed in triplicate and standardized to GAPDH levels. The
sequences of primers (TaKaRa) are as follows:
PSM-RB1-F 5′-CAACTGCACAGTGAATCCAAAAGA-3′
PSM-RB1-R 5′-ATATGTGGCCATTACAACCTCAAG-3′
RB1-F 5′-GACCAACTGATCACCTTGAATC-3′
RB1-R 5′-ATTTCAATGGCTTCTGGGTCTG-3′
MCM2-F 5′-CTCAACCAGATGGACCAGGA-3′
MCM2-R 5′-TCGATCACATAGTCCCgCAGA-3′
MCM4-F 5′-AGCATGGCACTCATCCACAAC-3′
MCM4-R 5′-TCAACGAGATCATTGTGCAAA-3′
MCM7-F 5′-GCTGATGCCGTACAAGAG-3′
MCM7-R 5′-AGCAGGGTACTGGTTCTG-3′
Flow cytometry. For cell-cycle analysis, cells were fixed in 70% ethanol for at
least 1 h at 4 °C. Then cells were washed and resuspended in 1 ml PBS containing
8 μg RNAse A and 50 μg propidium iodide. The cell suspensions were incubated in
the dark at room temperature for 30 min prior to FACS analysis. Flow cytometry was
performed on a Becton Dickinson Canto instrument (BD Biosciences, San Jose,
CA, USA) and red fluorescence PI-labeled cells were measured through a 600 nm
wave-length filter. Analysis was performed according to the manufacturer’s
instructions.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde and
permeabilized with 0.1% Triton-X100. Anti-mouse and anti-rabbit Alexa Fluor
488 secondary antibodies were from Invitrogen. Images were taken by a Leica TCS
SP5 II Microscope (Leica, Wetzlar, Germany).
Immunohistochemistry staining. Tissues were fixed in 10% neutralized
formaldehyde for 24 h and embedded in paraffin. Primary antibodies anti-MCM7
and anti-RB (1:50 dilution) were applied overnight at 4 °C, followed by a second
antibody for 30 min at room temperature. Images were taken by a Leica SCN400
slide scanner (Leica).
Chromosomal instability assays. Cells were treated with 0.5% μg/ml
colchicine for 4 h at 37 °C before collection. To prepare metaphase chromosome
spreads, cells were resuspended in 0.56 M KCl, incubated for 25 min at 37 °C,
centrifuged and resuspended in fixation solution (3:1 vol/vol methanol/acetic acid) for
5 min at 37 °C. Cells were dropped onto microscope slides and dried for 2 h at 65 °C.
Images were recorded with a chromosome karyotype analyzer (ZEISS, Oberkochen,
Germany).
ELISA buffers and antigen preparation. The ELISA buffers used
regularly include (a) coating buffer, 50 mM carbonate buffer (pH 9.6):1.59 g
Na2CO3, 2.93 g NaHCO3 in 1 l distilled water; (b) dilution buffer, 10 mM PBS
(pH = 7.4): 2.9 g Na2HPO4·12H2O, 8 g NaCl, 0.2 g KCl and 0.2 g KH2PO4 in 1 l
distilled water; (c) washing buffer (PBST), 10 mM PBS (pH 7.4) containing 0.05%
(v/v) Tween 20; (d) double blocking buffer, 10 mM PBS (pH 7.4) containing 0.05%
(m/v) BSA and 0.05% (m/v) skim milk powder solution; (e) TMB solution, 1 ml
sodium citrate buffer (pH 3.6) containing10 μl 10 mg/ml TMB and 1 μl 30% (v/v)
H2O2; and (f) stop solution: 2 M H2SO4.
Hep3B was cultured in high-glucose DMEM medium supplemented with 10% FSB
and 88 compounds of Selleck Customized Library as complete medium for 72 h.
Cells were washed in PBS and scraped and whole-cell lysates were prepared and
centrifuged at 12 000 r.p.m. for 10 min at 4 °C.
Detection of MCM7 by double antibody sandwich ELISA. The
microwells of the ELISA plate were coated with MCM7 capture antibody (SC-9966)
in coating buffer at 4 °C overnight. Three washes with washing buffer were
performed to remove unbound antibody and each well was blocked with 200 μl of
0.05% skim milk powder and incubated at 37 °C for 60 min. Add 100 μl sample per
well. Cover with the bottom of microwells. Incubate for 2 h at room temperature.
Washes were repeated and 100 μl of the Detection antibody (CST-4018) at a
1:1000 dilution in PBS was added to each well and incubated at 37 °C for 30 min.
Washing was repeated and 100 μl goat anti-Rabbit IgG horseradish peroxidase
conjugate (at a 1:5000 dilution in PBS) was then added to each well and was
incubated at 37 °C for 30 min. The plate was then washed three times and 100 μl of
TMB solution was added to each well and incubated at 37 °C for 15 min. The
reaction was then terminated by the addition of 50 μl of 2 M H2SO4 and the
absorbance values at 450 nm were measured.
Animals. The mice were from Laboratory Animal Center of Xi’an Jiaotong
University (Xi’an, China). The experimental protocol was approved by the Ethical
Committee and the Institutional Animal Care and Use Committee of Xi’an Jiaotong
University. B16 cells (1 × 106 cells) were injected subcutaneously into female C57/B16
mice (6–8 weeks, body weight 20 g). 4TI cells (5 × 105 cells) were injected into the fat
pad of female BalB/C mice (6–8 weeks, body weight 20 g). SiHa cells or SiHa
knockdown RB cells (1 × 106 cells) were injected subcutaneously into female nude
mice (6–8 weeks, body weight 20 g). The mice received 60 mg/kg/day SVA by gavage.
Statistical analysis. Each experiment was repeated at least three times.
Results are expressed as mean± S.D. or S.E.M. as indicated. Statistical analysis
was performed using GraphPad Prism 5 and presented in the following manners:
*Po0.05, **Po0.01 and ***Po0.001.
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